RecruitMe Clinical Trial
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
| Sponsor: | Pfizer |
| Enrolling: | Male and Female Patients |
| Age Range: | Between 2 and 21 years old |
| IRB Number: | AAAS2961 |
| U.S. Government ID: | NCT03709680 |
| Contact: | Rebecca Zylber, NP: 212-305-7212 / rjv2107@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to find the best dose of Palbociclib that can be given safely with chemotherapy in children with solid tumor which has come back or has not responded to the standard therapy. Palbociclib works by targeting proteins that are necessary for cell growth. Palbociclib will be given by mouth on Days 1-14 of a 21-day cycle. It will be given in combination with chemotherapy drugs Irinotecan and Temozolomide.
